Table 1.
Baseline characteristics of the enrolled patients who received lenvatinib or sorafenib as a salvage treatment after transarterial treatment failure.
| Parameters | Lenvatinib (N = 43) |
Sorafenib (N = 55) |
Total (N = 98) |
p |
|---|---|---|---|---|
| Epidemiology | ||||
| Sex, M/F (%) | 35 (81.4)/8 (18.6) | 42 (76.4)/13 (23.6) | 77 (78.6)/21 (21.4) | 0.723 |
| Age, median (range) | 60 (32–85) | 63 (43–86) | 62.5 (32–86) | 0.451 |
| Etiology | 0.881 | |||
| HBV, n (%) | 31 (72.1) | 42 (76.4) | 73 (74.5) | |
| HCV, n (%) | 3 (7.0) | 2 (3.6) | 5 (5.1) | |
| Alcohol, n (%) | 7 (16.3) | 8 (14.5) | 15 (15.3) | |
| Others, n (%) | 2 (4.7) | 3 (5.5) | 5 (5.1) | |
| Child-Pugh score | 0.289 | |||
| 5, n (%) | 24 (55.8) | 37 (67.3) | 61 (62.2) | |
| 6, n (%) | 13 (30.2) | 15 (27.3) | 28 (28.6) | |
| 7, n (%) | 6 (14.0) | 3 (5.5) | 9 (9.2) | |
| BCLC stage | 0.792 | |||
| A, n (%) | 0 (0) | 0 (0) | 0 (0) | |
| B, n (%) | 8 (18.6) | 8 (14.5) | 16 (16.3) | |
| C, n (%) | 35 (81.4) | 47 (85.5) | 82 (83.7) | |
| D, n (%) | 0 (0) | 0 (0) | 0 (0) | |
| ECOG | 0.942 | |||
| 0, n (%) | 16 (37.2) | 22 (40.0) | 38 (38.8) | |
| 1, n (%) | 27 (62.8) | 33 (60.0) | 60 (61.2) | |
| AFP, median (range), ng/mL | 278.9 (1.4–115807) | 708.8 (1.3–512682) | 647.4 (1.3–512682) | 0.463 |
| PIVKA-II, median(range), mAU/mL | 806 (11–300000) | 532.3 (14–52576) | 638.3 (11–300000) | 0.020 |
| Macrovascular invasion, n (%) | 19 (44.2) | 25 (45.5) | 44 (44.9) | 1.000 |
| Extrahepatic metastasis, n (%) | 24 (55.8) | 39 (70.9) | 63 (64.3) | 0.182 |
| Previous treatments | ||||
| TACE, n (%) | 40 (93.0) | 54 (98.2) | 94 (95.9) | |
| HAIC, n (%) | 8 (20.9) | 4 (7.3) | 12 (12.2) | |
| Radiation therapy, n (%) | 13 (30.2) | 14 (25.5) | 27 (27.6) | |
| Surgical resection, n (%) | 5 (11.6) | 9 (16.4) | 14 (14.3) | |
| Radiofrequency ablation, n (%) | 5 (11.6) | 8 (14.5) | 13 (13.3) | |
| Systemic chemotherapy, n (%) | 5 (11.6) | 1 (1.8) | 6 (6.1) |
HBV, Hepatitis B virus; HCV, Hepatitis C virus; AFP, Alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence-II; TACE, Transarterial chemoembolization; HAIC, Hepatic arterial infusion chemotherapy.